Mylan Launches Generic Cancer Drug Bexarotene

Mylan has launched in the United States, bexarotene 75 mg capsules, which is the generic version of Valeant’s Targretin capsules. This product is indicated for the treatment of cutaneous manifestations of cutaneous t-cell lymphoma in patients who are refractory to at least one prior systemic therapy.

Bexarotene 75 mg capsules had US sales of approximately $155.5 million for the 12 months ending March 31, 2015, according to IMS Health, and as reported by Mylan.

Source: Mylan

Leave a Reply

Your email address will not be published. Required fields are marked *